Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.57 |
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16506371 | 0.77 | KMO (0.62) | KMOSTING1LTC4SGRM4 | |
| SCHEMBL5561431 | 0.75 | KMO (0.47) | KMOSTING1KMT2ALTC4SGRM4 | |
| SCHEMBL1771714 | 0.73 | — | — | |
| SCHEMBL940660 | 0.73 | — | — | |
| SCHEMBL5091159 | 0.73 | KMO (0.67) | KMOMAPTKMT2ALTC4S | |
| SCHEMBL5099408 | 0.73 | KMO (0.67) | KMOMAPTKMT2ALTC4S | |
| SCHEMBL5091162 | 0.73 | KMO (0.67) | KMOMAPTKMT2ALTC4S | |
| SCHEMBL4753610 | 0.72 | KMO (1.00) | KMOMAPTKMT2ALTC4S | |
| SCHEMBL5560977 | 0.72 | KMO (0.45) | KMOSTING1MAPTKMT2ALTC4S | |
| SCHEMBL21974233 | 0.72 | KMO (1.00) | KMOMAPTKMT2ALTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565451-B1 | HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-05-09 | — | — | EP | claimed |
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2006-06-01 | — | — | US | claimed |
| EP-1565451-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2005-08-24 | — | — | EP | claimed |
| WO-2004048361-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2004-06-10 | — | — | WO | claimed |
| EP-1424333-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | claimed |
| EP-1565451-B1 | HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-05-09 | — | — | EP | disclosed |
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2006-06-01 | — | — | US | disclosed |
| EP-1565451-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048361-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2004-06-10 | — | — | WO | disclosed |
| EP-1424333-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | KMO, HAO1, DAO | KMO 1/4885DAO 3/4885STING1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.